Question 1

What is combined oxidative phosphorylation defect type 13?

Accepted Answer

Combined oxidative phosphorylation defect type 13 is a rare mitochondrial disorder that affects energy production and muscle function. It is caused by defects in mitochondrial protein synthesis due to variants in the PNPT1 gene. The condition typically presents in infancy, following a period of typical early development, with symptoms such as poor feeding and decreased muscle tone. It is very rare, affecting fewer than 1 in a million people.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 13?

Accepted Answer

After a period of apparently typical early development, affected children experience a phase of developmental regression marked by loss of previously acquired motor skills. Clinically, infants present with poor feeding, dysphagia, and truncal hypotonia that later becomes more generalized. Neurological involvement is evident, with characteristic findings such as hyporeflexia, decreased nerve conduction velocity, encephalopathy, choreoathetosis, dystonia, and abnormal movements including facial dyskinesias. Additional features observed in some individuals include skeletal muscle atrophy and feeding difficulties, while increased lactate levels in both cerebrospinal fluid and blood are consistently documented. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation defect type 13?

Accepted Answer

This condition results from pathogenic variants in the PNPT1 gene, which plays an important role in mitochondrial protein synthesis. It is inherited in an autosomal recessive manner, meaning that an affected individual has two altered copies of the gene, one inherited from each parent. In autosomal recessive conditions, the chance of both parents carrying the same rare variant is increased when they share a common ancestor. Genetic counseling is recommended for families to discuss inheritance, recurrence risks, and family planning options. Associated genes include PNPT1.

Question 4

How is combined oxidative phosphorylation defect type 13 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 13 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 13?

Accepted Answer

combined oxidative phosphorylation defect type 13 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 13 diagnosed?

Accepted Answer

The definitive diagnosis is made through molecular genetic testing that identifies pathogenic variants in PNPT1. Clinical evaluation, including an assessment of the characteristic neurological and muscular findings along with laboratory studies that reveal elevated lactate levels, supports the diagnosis. Because many of these features can be seen in other conditions, genetic testing is essential to confirm the diagnosis.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 13?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as no specific foundational or targeted therapies are available for combined oxidative phosphorylation defect type 13. Treatment is tailored to the individual and typically involves a multidisciplinary team that may include neurologists, metabolic specialists, and physical therapists. Regular surveillance is an essential part of long-term care, helping to identify potential complications before they become serious. Genetic counseling is recommended to provide further guidance on family planning and to help families navigate the complexities of this condition.

Question 8

What complications should we watch for with combined oxidative phosphorylation defect type 13?

Accepted Answer

With combined oxidative phosphorylation defect type 13, families should be aware of potential complications such as feeding difficulties and muscle weakness. Some children may also experience neurological issues like abnormal movements and decreased reflexes. Regular check-ups with healthcare providers can help monitor these complications and provide timely interventions.

Question 9

How does combined oxidative phosphorylation defect type 13 affect daily life for my child?

Accepted Answer

Daily life for a child with combined oxidative phosphorylation defect type 13 may involve challenges like poor feeding and decreased muscle tone. This can affect their ability to participate in typical activities, and they may require extra support for feeding and mobility. Families often work with a team of specialists to create a care plan that addresses their child's unique needs.

Question 10

What is the prognosis for children with combined oxidative phosphorylation defect type 13?

Accepted Answer

The prognosis for children with combined oxidative phosphorylation defect type 13 can vary widely. While the disease is severe during the initial regression phase, many children stabilize afterward with appropriate care. Outcomes depend on factors like symptom severity and access to specialized healthcare, so it's important for families to stay connected with their healthcare team.

Question 11

What specialists should we consult for combined oxidative phosphorylation defect type 13?

Accepted Answer

Families dealing with combined oxidative phosphorylation defect type 13 should consider consulting a team of specialists, including neurologists and metabolic specialists. Physical therapists can also be helpful for managing muscle function and mobility. Working with a multidisciplinary team ensures that all aspects of the child's care are addressed effectively.

Kisho

combined oxidative phosphorylation defect type 13

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

combined oxidative phosphorylation defect type 13

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 13?

What are the symptoms of combined oxidative phosphorylation defect type 13?

What causes combined oxidative phosphorylation defect type 13?

How is combined oxidative phosphorylation defect type 13 inherited?

How rare is combined oxidative phosphorylation defect type 13?

How is combined oxidative phosphorylation defect type 13 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 13?

What complications should we watch for with combined oxidative phosphorylation defect type 13?

How does combined oxidative phosphorylation defect type 13 affect daily life for my child?

What is the prognosis for children with combined oxidative phosphorylation defect type 13?

What specialists should we consult for combined oxidative phosphorylation defect type 13?

Explore clinical features